Compare AISP & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | COEP |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | United States | United States |
| Employees | 63 | 6 |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.7M | 91.2M |
| IPO Year | N/A | N/A |
| Metric | AISP | COEP |
|---|---|---|
| Price | $2.52 | $16.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 467.9K | 60.9K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $222.88 | N/A |
| Revenue Next Year | $5.36 | N/A |
| P/E Ratio | $3.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $6.80 |
| 52 Week High | $7.20 | $21.41 |
| Indicator | AISP | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 54.73 | 72.18 |
| Support Level | $2.07 | $13.77 |
| Resistance Level | $2.82 | $19.19 |
| Average True Range (ATR) | 0.15 | 1.15 |
| MACD | 0.02 | 0.47 |
| Stochastic Oscillator | 61.36 | 87.62 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture. Airship AI's software allows customers to view structured data both in real-time as well as to conduct searches on the structured data at a later point in time.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical and technology company. The biopharmaceutical division focuses on developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its research and development efforts. The technology division focuses on enhancing operational capabilities through technologies. This division features AI-powered marketing software and robotic process automation tools designed to optimize business processes and improve overall efficiency. It derives the majority of the revenue from the Technology segment.